Therapy Areas: Hereditary Disorders
Endo Ventures signs development and distribution contract with Quoin Pharmaceuticals
18 July 2022 -

Ireland-based Endo International plc (NASDAQ: ENDP) announced on Friday that its subsidiary Endo Ventures Limited has signed contract with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX), an Israel-based specialty pharmaceutical company, for the development, registration, supply, commercialisation and distribution of Quoin's QRX003 on an exclusive basis in Canada.

QRX003 is Quoin's lead product for Netherton syndrome, a rare, hereditary disorder.

If QRX003 receives approval, Paladin Labs Inc., an Endo operating company, will handle all commercial activities in Canada. Presently, Paladin is expecting to introduce the product in Canada in 2025.

Login
Username:

Password:


Related Headlines

Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206

US FDA Approves Orkambi in Children with Cystic Fibrosis Ages 12 to <24 Months

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

EpiAxis Therapeutics and Peptilogics Enter Strategic Drug Discovery Partnership

Vicinitas Therapeutics Launches with USD 65m in Series A Financing

Endo Ventures signs development and distribution contract with Quoin Pharmaceuticals

ReCode Therapeutics Closes Series B Extension Financing Round

First Two Patients Dosed in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

Health Canada Grants Marketing Authorization for Trikafta in Children with Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

Cystic Fibrosis Foundation Invests USD 5m in Sionna Therapeutics to Develop New CFTR Modulator Therapy

Laurent Pharmaceuticals Starts Phase 3 Study with Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

Cyclica Launches University of Toronto Spinout Perturba Therapeutics

Northwestern Medicine's study shows lung transplantation highly effective and successful in critically-ill COVID-19 patients

Arcturus Therapeutics Posts New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

European Commission Approves Kaftrio in Combination with Ivacaftor to Treat Children with Cystic Fibrosis Ages 6 to 11 Years